mdbrain is a software solution powered by artificial intelligence (AI) for volumetric brain analysis and the characterization of white matter lesions. It uses a combination of several deep learning methods to derive reliable data from MR images. The solution integrates with the PACS and provides quantitative reports. Through a browser-based platform the system can be supervised. Local installation keeps patient data within the centre.
Product specifications Information source: Vendor
Last updated: March 23, 2020
Product name mdbrain
Company mediaire
Subspeciality Neuro
Modality MR
Disease targeted dementia, NPH, multiple sclerosis, neurodegenerative diseases, vascular dementia
Key-features brain volume quantification (global, regional down to Hippocampus, ventricles), white/grey matter quantification, white matter lesion detection and progression tracking
Suggested use Before: stratifying reading process (non, single, double read)
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), interactive 3D-annotation viewer for white matter lesions
Data characteristics
Population early diagnosis and follow up of neurodegenerative diseases like dementia and auto-immune diseases like multiple sclerosis
Input 1.5 or 3T MR by Siemens, Philips or GE
Input format DICOM
Output table of quantified values, tables and schematics with color coded deviations from normal database, segmentation overlay, lesion annotations, classification of lesions as MS-specific
Output format PDF, DICOM-PDF, browser-based platform, CSV-Export file
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker)
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
CE Certified, Class I
FDA No or not yet
Market presence
On market since 01/2019
Distribution channels Direct and several platforms including QMENTA Trials & TELEPAXX
Countries present (clinical, non-research use) 3 (Germany, Switzerland & Austria)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use
Based on Number of analyses
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers